Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) EBT (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed EBT for 16 consecutive years, with $4.4 million as the latest value for Q4 2025.

  • Quarterly EBT fell 40.89% to $4.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.2 million through Dec 2025, up 105.44% year-over-year, with the annual reading at $18.2 million for FY2025, 105.44% up from the prior year.
  • EBT for Q4 2025 was $4.4 million at Niagen Bioscience, down from $4.8 million in the prior quarter.
  • The five-year high for EBT was $7.5 million in Q4 2024, with the low at -$8.9 million in Q3 2021.
  • Average EBT over 5 years is -$1.2 million, with a median of -$1.2 million recorded in 2022.
  • The sharpest move saw EBT tumbled 110.11% in 2021, then soared 25013.33% in 2025.
  • Over 5 years, EBT stood at -$5.3 million in 2021, then skyrocketed by 72.88% to -$1.4 million in 2022, then skyrocketed by 107.89% to $114000.0 in 2023, then soared by 6464.91% to $7.5 million in 2024, then plummeted by 40.89% to $4.4 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at $4.4 million, $4.8 million, and $3.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.